双表达淋巴瘤的诊断前沿及治疗进展

Diagnostic frontiers and treatment advances of double-expressor Lymphoma

弥漫性大B细胞淋巴瘤(DLBCL)可通过标准的一线免疫化疗治愈,但仍有30%~40%的患者会出现难治或复发,其中双表达淋巴瘤(DEL)约占复发/难治DLBCL患者的50%。寻求提高DEL患者疗效的诊治策略至关重要。近年来,液体活检技术等新型诊断技术在DLBCL的应用为其在DEL诊治中的研究和应用前景提供了潜在的可行性。靶向药物联合化疗、造血干细胞移植、嵌合抗原受体T细胞治疗等治疗手段被发现可能会为DEL患者带来临床获益。因此,该文旨在对DEL的诊断前沿及治疗进展进行系统综述,展望DEL诊治的有效策略。

Diffuse large B-cell lymphoma(DLBCL)can be cured with standard first-line immunochemotherapy,but nearly 30%-40%of patients will still be refractory or relapsed,with double-expressor lymphoma(DEL)accounting for about 50%of patients with relapsed/refractory DLBCL.It is important to seek diagnostic and therapeutic strategies that improve outcomes for patients with DEL.In recent years,the application of new diagnostic techniques such as liquid biopsy technology in DLBCL has provided potential feasibility for the research and application prospects in the diagnosis and treatment of DEL.Targeted drugs combined with chemotherapy,hematopoietic stem cell transplantation,CAR-T cell therapy and other therapeutic methods have been found to bring clinical benefits to DEL patients.Therefore,this article aims to systematically review the diagnostic frontiers and treatment progress of DEL,and to prospect effective strategies for the diagnosis and treatment of DEL.